Treating muscular dystrophy by stimulating intrinsic repair

Regenerative Medicine

Volumn 8, Issue 3, 2013, Pages 237-240

  Wang, Yu Xin ^a,b   Bentzinger, C Florian ^a   Rudnicki, Michael A ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

biologics; cell therapy; muscle stem cells; muscular dystrophy; satellite cells; skeletal muscle; small molecular compounds; stem cell mobilization

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; MITOGEN ACTIVATED PROTEIN KINASE P38; WNT7A PROTEIN;

BECKER MUSCULAR DYSTROPHY; DUCHENNE MUSCULAR DYSTROPHY; ENGRAFTMENT; EXTRACELLULAR MATRIX; GENE MUTATION; GENE THERAPY; HUMAN; MUSCULAR DYSTROPHY; NERVE REGENERATION; NOTE; PRIORITY JOURNAL; SKELETAL MUSCLE SATELLITE CELL; STEM CELL TRANSPLANTATION;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL; WOUND HEALING;

EID: 84876942929     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.27     Document Type: Note

References (20)

1. Rüegg MA, Glass DJ. Molecular mechanisms and treatment options for muscle wasting diseases. Annu. Rev. Pharmacol. Toxicol. 51, 373-395 (2011).
2. Bentzinger CF, Wang YX, Rudnicki MA. Building muscle: molecular regulation of myogenesis. Cold Spring Harb. Perspect. Biol. 4(2), a008342 (2012).
3. Bentzinger CF, Wang YX, von Maltzahn J, Rudnicki MA. The emerging biology of muscle stem cells: implications for cell-based therapies. Bioessays 35(3), 231-241 (2013).
4. Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of Duchenne muscular dystrophy. Curr. Neurol. Neurosci. Rep. 13(3), 332 (2013).
5. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 6(6), 517-520 (2010).
6. Phillips MI. Gene, stem cell, and future therapies for orphan diseases. Clin. Pharmacol. Ther. 92(2), 182-192 (2012).
7. Buyse GM, Van der Mieren G, Erb M et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur. Heart J. 30(1), 116-124 (2009).
8. Manzur AY, Kuntzer T, Pike M, Swan AV. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 1, CD003725 (2008).
9. Erb M, Meinen S, Barzaghi P et al. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J. Pharmacol. Exp. Ther. 331(3), 787-795 (2009).
10. Phillips MF, Quinlivan R. Calcium antagonists for Duchenne muscular dystrophy. Cochrane Database Syst. Rev. (4), CD004571 (2008).
11. Grumati P, Coletto L, Sabatelli P et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat. Med. 16(11), 1313-1320 (2010).
12. Weisleder N, Takizawa N, Lin P et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci. Transl. Med. 4(139), 139ra85 (2012).
13. Tinsley JM, Fairclough RJ, Storer R et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE 6(5), e19189 (2011).
14. Rooney JE, Gurpur PB, Burkin DJ. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc. Natl Acad. Sci. USA 106(19), 7991-7996 (2009).
15. Amthor H, Hoogaars WMH. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. Curr. Gene Ther. 12(3), 245-259 (2012).
16. Mann CJ, Perdiguero E, Kharraz Y et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle 1(1), 21 (2011).
17. Beytía Mde L, Vry J, Kirschner J. Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives. Acta Myol. 31(1), 4-8 (2012).
18. Wu Z, Woodring PJ, Bhakta KS et al. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol. Cell. Biol. 20(11), 3951-3964 (2000).
19. Jones NC, Tyner KJ, Nibarger L et al. The p38alpha/beta MAPK functions as a molecular switch to activate the quiescent satellite cell. J. Cell Biol. 169(1), 105-116 (2005).
20. von Maltzahn J, Renaud J-M, Parise G, Rudnicki MA. Wnt7a treatment ameliorates muscular dystrophy. Proc. Natl Acad. Sci. USA 109(50), 20614-20619 (2012).